JAK2 and essential thrombocythemia: JAK2 mutations affecting the JAK-STAT signal transduction pathway are found in 90%-95% of patients with polycythemia vera (PV) [3], 50%-70% of patients with essential thrombocythemia (ET), and 40%-50% of patients with primary myelofibrosis (PMF) [4].